Courtney Marabella

Senior Editor, OncLive®
Courtney Marabella joined the MJH Life Sciences team in 2021 and is Senior Editor for OncLive®. Prior to joining the company she worked as the Audience Development Editor for the Asbury Park Press, part of the USA Today Network. Email:


Enrollment Begins for Part 2 of LEAP-006 Trial Examining Novel Pembrolizumab Combo in Metastatic NSCLC

October 14th 2021

Because the combination of pembrolizumab, lenvatinib, and platinum-based chemotherapy showed early evidence of antitumor activity with a manageable safety profile in previously untreated patients with metastatic nonsquamous non–small cell lung cancer examined in part 1 of the phase 3 LEAP-006 trial, the second part of the research has officially begun enrollment.

Trastuzumab Duocarmazine Produces PFS Benefit in Pretreated HER2+ Breast Cancer

October 12th 2021

Vic-trastuzumab duocarmazine markedly improved progression-free survival vs physician’s choice of treatment in patients with HER2-positive metastatic breast cancer who had received 2 prior treatment regimens or ado-trastuzumab emtansine in the metastatic setting, according to data from the phase 3 TULIP trial.

Nivolumab/Cabozantinib Continues to Showcase Deep, Durable Responses in Advanced RCC

October 11th 2021

Nivolumab plus cabozantinib continued to significantly improve overall response rate vs sunitinib in patients with previously untreated, advanced renal cell carcinoma, with meaningful response outcomes observed irrespective of dose modifications with cabozantinib and fewer responders in the doublet arm requiring subsequent treatment.

Autologous HSCT Shows Sustained Long-Term Benefit in MCL, But Role May Be Rechallenged By Novel Approaches

October 11th 2021

Autologous hematopoietic stem-cell transplantation maintained its long-term efficacy over interferon alfa in patients with mantle cell lymphoma, confirming its place as the standard frontline treatment in this population.

Reiss Shares Secrets Behind Optimal Molecular Testing Approaches in NSCLC

October 6th 2021

Pivotal trials, such as the phase 3 FLAURA trial with osimertinib in patients with EGFR-mutant non–small cell lung cancer NSCLC, have demonstrated the significant benefit yielded with targeted therapies.

Vimseltinib Demonstrates Encouraging Preliminary Efficacy, Tolerability in TGCTVimseltinib Demonstrates Encouraging Preliminary Efficacy, Tolerability in TGCT

October 6th 2021

Vimseltinib was well tolerated and demonstrated promising preliminary efficacy in patients with tenosynovial giant cell tumors whose tumors are not amendable to surgical resection, according to results from a phase 1/2 study.

Plinabulin/Docetaxel Demonstrates Durable Antitumor Benefit in EGFR Wild-Type NSCLC

October 6th 2021

The addition of plinabulin to docetaxel demonstrated durable anticancer benefit in terms of overall survival when used in the second- or third-line treatment of patients with EGFR wild-type non–small cell lung cancer who had progressed on a prior platinum-based regimen.

Triplet Combo Produces Promising Preliminary Activity in BRAF V600E–Mutant Metastatic CRC

October 5th 2021

The triplet combination comprised of encorafenib, binimetinib, and cetuximab elicited encouraging responses with a manageable safety profile in patients with previously untreated BRAF V600E–mutant metastatic colorectal cancer, meeting the primary end point of the phase 2 ANCHOR-CRC trial.

Sacituzumab Govitecan Significantly Improves HRQoL Vs Physician’s Choice in mTNBC

October 5th 2021

Sacituzumab govitecan-hziy resulted in a statistically significant and clinically meaningful improvement in health-related quality of life compared with single-agent chemotherapy of physician’s choice in patients with metastatic triple-negative breast cancer.

6-Month Antibody Response to COVID-19 Vaccines Remains Similar in Patients With Solid Tumors Vs General Population

October 2nd 2021

Six months after receiving a second dose of the Pfizer-BioNTech COVID-19 vaccine, patients with solid tumors retained similar levels of COVID-19 antibodies in their blood as individuals without cancer.

Addition of Olaparib to Abiraterone Improves rPFS in mCRPC

September 24th 2021

Olaparib in combination with abiraterone acetate demonstrated a significant and clinically meaningful improvement in radiographic progression-free survival vs abiraterone alone as a first-line treatment for patients with metastatic castration-resistant prostate cancer with or without homologous recombination repair gene mutations.

Pelabresib/Ruxolitinib Combo Shows Promising Management in Myelofibrosis

September 22nd 2021

The phase 1/2 MANIFEST and phase 3 MANIFEST-2 trials are examining a complement to JAK inhibition that could improve responses and disease management up front in patients with myelofibrosis.

Durvalumab Plus Chemotherapy Showcases Sustained OS Benefit in ES-SCLC

September 21st 2021

The addition of durvalumab to platinum/etoposide chemotherapy continued to demonstrate an overall survival benefit over chemotherapy alone with a favorable safety profile in patients with extensive-stage small cell lung cancer.

Giredestrant Induces Greater Ki-67 Suppression Vs Anastrozole in ER+/HER2– Early Breast Cancer

September 21st 2021

Giredestrant resulted in a greater relative reduction in Ki67 score from baseline to week 2 of a window of opportunity phase vs anastrozole in patients with estrogen receptor–positive, HER2-negative early breast cancer, according to results from an interim analysis of the phase 2 coopERA Breast Cancer trial.

Ribociclib/Letrozole Combo Yields Significant OS Benefit in Postmenopausal HR+/HER2- Advanced Breast Cancer

September 19th 2021

The combination of ribociclib and letrozole demonstrated a statistically significant and clinically meaningful overall survival benefit compared with letrozole alone in the first-line setting for postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer, according to results from the phase 3 MONALEESA-2 trial.

Novel Immunotherapy Options Prompt Paradigm Shift in NSCLC Treatment

September 18th 2021

A shift in the NSCLC treatment paradigm came in the form of immunotherapy, which has since seen significant progress—mostly in the past decade.

TMB-H Status Linked With High Responses to Dostarlimab in Endometrial Cancer

September 16th 2021

Patients with endometrial cancer who had a high tumor mutational burden experienced high responses to single-agent dostarlimab-gxly, irrespective of mismatch repair or microsatellite stability status.

Olaparib Maintains Benefit Over Enzalutamide or Abiraterone in mCRPC

September 14th 2021

Olaparib was still found to produce greater clinical benefit than enzalutamide or abiraterone acetate in patients with metastatic castration-resistant prostate cancer when the novel hormonal agents were examined separately rather than combined.

Enzalutamide/ADT Maintains Efficacy Regardless of Prior Antiandrogen Therapy in mHSPC

September 12th 2021

Enzalutamide plus androgen-deprivation therapy produced clinical benefit over ADT alone in patients with metastatic hormone-sensitive prostate cancer, regardless of prior antiandrogen therapy and its pretreatment duration.

N-803/BCG Combo Shows Promising Responses, Tolerability in BCG-Unresponsive Bladder Cancer

September 10th 2021

Bacille Calmette-Guérin (BCG) plus N-803 yielded promising responses and an encouraging safety profile in patients with BCG-unresponsive, non-muscle invasive bladder cancer carcinoma in situ.